Literature DB >> 33557137

Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.

Julian Bailes1, Mikhail Soloviev1.   

Abstract

Insulin-like growth factor-1 (IGF-1) is the principal mediator of growth hormone (GH), plays a crucial role in promoting cell growth and differentiation in childhood and continues to have an anabolic effect in adults. IGF-1 is part of a wide network of growth factors, receptors and binding proteins involved in mediating cellular proliferation, differentiation and apoptosis. Bioavailability of IGF-1 is affected by insulin-like growth factor binding proteins (IGFBPs) which bind IGF-1 in circulation with an affinity equal to or greater than that of the IGF-1 receptor (IGF-1R). The six IGFBPs serve as carrier proteins and bind approximately 98% of all circulating IGF-1. Other proteins known to bind IGF-1 include ten IGFBP-related proteins (IGFBP-rPs), albeit with lower affinities than the IGFBPs. IGF-1 expression levels vary in a number of clinical conditions suggesting it has the potential to provide crucial information as to the state of an individual's health. IGF-1 is also a popular doping agent in sport and has featured in many high-profile doping cases in recent years. However, the existence of IGFBPs significantly reduces the levels of immunoreactive IGF-1 in samples, requiring multiple pre-treatment steps that reduce reproducibility and complicates interpretation of IGF-1 assay results. Here we provide an overview of the IGF network of growth factors, their receptors and the entirety of the extended family of IGFBPs, IGFBP-rPs, E peptides as well as recombinant IGF-1 and their derivatives. We also discuss issues related to the detection and quantification of bioavailable IGF-1.

Entities:  

Keywords:  ALS; IGF; IGF-1R; IGF-2R; IGFBP; IGFBP-rP; IGFBPL1; doping; insulin; insulin-like growth factor

Year:  2021        PMID: 33557137      PMCID: PMC7913862          DOI: 10.3390/biom11020217

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  114 in total

1.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study.

Authors:  J V Lacey; A W Hsing; C M Fillmore; S Hoffman; K J Helzlsouer; G W Comstock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-10       Impact factor: 4.254

2.  A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial.

Authors:  François Meyer; Pilar Galan; Pierre Douville; Isabelle Bairati; Pastelle Kegle; Sandrine Bertrais; Sébastien Czernichow; Serge Hercberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-09       Impact factor: 4.254

3.  Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples.

Authors:  Hermien Hartog; Winette T A van der Graaf; Jelle Wesseling; Eveline van der Veer; H Marike Boezen
Journal:  Clin Biochem       Date:  2008-02-15       Impact factor: 3.281

4.  Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch.

Authors:  S Yang; M Alnaqeeb; H Simpson; G Goldspink
Journal:  J Muscle Res Cell Motil       Date:  1996-08       Impact factor: 2.698

5.  The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.

Authors:  Richard I G Holt; Ioulietta Erotokritou-Mulligan; Cathy McHugh; E Eryl Bassett; Christiaan Bartlett; Adam Fityan; Jenny L Bacon; David A Cowan; Peter H Sönksen
Journal:  Eur J Endocrinol       Date:  2010-04-26       Impact factor: 6.664

6.  Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily.

Authors:  C P Burren; E M Wilson; V Hwa; Y Oh; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

7.  Normal growth and development in the absence of hepatic insulin-like growth factor I.

Authors:  S Yakar; J L Liu; B Stannard; A Butler; D Accili; B Sauer; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

8.  Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.

Authors:  F M Tomas; S E Knowles; P C Owens; C S Chandler; G L Francis; L C Read; F J Ballard
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

Review 9.  Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Authors:  Martin Bidlingmaier; Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

10.  Young women with type 1 diabetes have lower bone mineral density that persists over time.

Authors:  Lucy D Mastrandrea; Jean Wactawski-Wende; Richard P Donahue; Kathleen M Hovey; Angela Clark; Teresa Quattrin
Journal:  Diabetes Care       Date:  2008-06-30       Impact factor: 19.112

View more
  3 in total

Review 1.  The role and function of CLU in cancer biology and therapy.

Authors:  Yefei Zhang; Xiang Lv; Liming Chen; Yan Liu
Journal:  Clin Exp Med       Date:  2022-09-13       Impact factor: 5.057

2.  Circulating Insulin-Like Growth Factor 1 Levels and Migraine Risk: A Mendelian Randomization Study.

Authors:  Reziya Abuduxukuer; Peng-Peng Niu; Zhen-Ni Guo; Yu-Ming Xu; Yi Yang
Journal:  Neurol Ther       Date:  2022-09-01

Review 3.  Pregnancy-Associated Plasma Protein (PAPP)-A2 in Physiology and Disease.

Authors:  Vicente Barrios; Julie A Chowen; Álvaro Martín-Rivada; Santiago Guerra-Cantera; Jesús Pozo; Shoshana Yakar; Ron G Rosenfeld; Luis A Pérez-Jurado; Juan Suárez; Jesús Argente
Journal:  Cells       Date:  2021-12-18       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.